Cellular toxicity – Cisplatin (cis-diamminedichloroplatinum II [CDDP]), a platinum compound that is predominantly eliminated through renal clearance.
When renally cleared drugs are administered to patients with reduced renal function, drug accumulation leading to supratherapeutic
In contrast, the subsequent beta elimination phase represents the renal clearance of inactive platinum species that did not correlate with drug toxicity.
Usually, a platinum drug (cisplatin or carboplatin) is combined The treatment of advanced non-clear cell renal carcinoma. UpToDate
Newer platinum agents such as this medication is not renally cleared and does not require dose adjustments in patients with renal insufficiency. Bortezomib should be given after dialysis in
by G Sandhu 2024concomitant nephrotoxic drug exposure (e.g, platinum drugs) and prior renally cleared drug as 30% the dose being eliminated unchanged in the
Impaired renal function can alter some drug metabolism and transport impairment to also affect drugs that are predominantly cleared non-renally.3,4
The first drug is usually a platinum product platinum product platinum is a metal and is an important ingredient in many anti-cancer drugs, either cisplatin
by WH Li 2024 Cited by 6The present study also shows that platinum is the main chemotherapy drug that causes renal impairment in elderly patients with malignant tumors.
Comments